Skip to main content
. 2022 Mar 2;21:15347354221078888. doi: 10.1177/15347354221078888

Figure 5.

Figure 5.

Effects of sorafenib combined with SDC on the expression of Ki67 and caspase 3 and the IHC scores for each group. The intensities of Ki-67 were decreased after combined therapy compared with the sorafenib or SDC mono-therapy using immunohistochemical (IHC), while caspase 3 was increased in the combination therapy. Magnification, ×100. *P < .05, **P< .01 versus the control group.